News

Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Texas Lawsuit Filed Against Eli Lilly (LLY) Amid New Cardio Collaboration

Eli Lilly (LLY) recently faced legal challenges as Texas Attorney General Ken Paxton filed a lawsuit against the company, ...

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...
PharmExec3h

Superluminal Medicines and Eli Lilly Form $1.3 Billion Collaboration Advancing Small Molecule Therapeutics

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
BioSpace1d

Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...
Becker's Hospital Review1h

Eli Lilly pushes back on proposed tariffs

Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access. The drugmaker said it has invested more than $50 billion ...